Newsquawk Logo

US FDA is planning to ease some requirements for drugmakers to develop copycat versions of expensive biologic medications, Bloomberg reports citing an FDA official

The FDA's move to ease requirements for developing copycat biologics signals a significant potential shift in the pharmaceutical landscape, likely increasing competition and lowering costs for these medications.

Newsquawk StaffPublished On the live feed at — 5 more headlines followed before this page went public
Newsquawk headlinesUTC

[MARKET ANALYSIS] DXY bid on haven flows, EUR eyes the G7 ministers meeting on energy for reprieve

Zurich Insurance (ZURN SW) to purchase Generali's (G IM) Irish unit for around EUR 337mln, Bloomberg reports citing sources

US FDA is planning to ease some requirements for drugmakers to develop copycat versions of expensive biologic medications, Bloomberg reports citing an FDA official

Nexperia BV rejects claims from Nexperia China that its access was restricted

Mizuho's Rochester writes "oil is now on a USD 100/bbl handle and it might be there to stay" with increasing likelihood of USD 130-150/bbl as the Middle East conflict/supply situation persists

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

This may not only benefit patients but could also impact the stock valuations of companies that produce these expensive drugs, as a more favorable environment for generics could threaten their market share. Traders should watch for market reactions in related sectors as this develops.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.